drug_type
RELEVANT_DRUG
intervention_type
Vaccine
drug_description
A nonreplicating modified vaccinia Ankara (MVA) recombinant viral-vector vaccine expressing CMV antigens IE1, IE2, and pp65; administered as two intramuscular doses (5.0 x 10^8 pfu) to elicit CMV-specific cellular immunity (CD8+ CTLs and CD4+ Th1) for prevention of primary CMV after D+R− liver transplant.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Cytomegalovirus Vaccines
drug_category
IMMUNOGENIC PROTEIN
drug_class
Vaccine
drug_delivery_route
Intramuscular
drug_mechanism_of_action
Nonreplicating MVA viral-vector vaccine that expresses CMV antigens IE1, IE2, and pp65 in host cells, leading to antigen presentation via MHC I/II by dendritic cells and induction of CMV-specific cellular immunity (CD8+ cytotoxic T cells and CD4+ Th1 responses) to prevent primary CMV infection post–liver transplant.
drug_name
CMV-MVA Triplex
nct_id_drug_ref
NCT06075745